Bajaj Healthcare rises after CDMO pact for 15 new Active Pharma Ingredients
Bajaj Healthcare saw a significant rise in its stock price after announcing a contract development and manufacturing organization (CDMO) agreement with UK and EU-based clients. The company has committed to supply 15 Active Pharmaceutical Ingredients (APIs) under this deal. These APIs, which include off-patent generics and some soon-to-be off-patent molecules, will be developed and manufactured exclusively for its clients at Bajaj's facility in Savli, Vadodara, Gujarat. Following the announcement, Bajaj Healthcare's stock surged by over 11%, reflecting investor optimism about the potential growth of the company and its expanded role in the global pharmaceutical supply chain

Comments
Post a Comment